1. Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection 
Alexander A. Navarini, MD, PhD, Lars E. French, MD, Günther F.L. Hofbauer, MD 
Journal of Allergy and Clinical Immunology 
Volume 128, Issue 5, Pages (November 2011)
DOI: /j.jaci
Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
A, Percentage of EASI scores over time, n = 3, 2-sided paired t test. B-D, EASI scores of patients over time: patient 1 (Fig 1, B), patient 2 (Fig 1, C), and patient 3 (Fig 1, D), with shaded boxes indicating treatment with tocilizumab and arrows indicating the administration of tocilizumab. E, Forearms of patient 2 over time, with relapse of clinical changes after missing 1 dose (compare with Fig 1, C).
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions